Literature DB >> 8520167

Suppression of pseudointimal hyperplasia by a novel prostacyclin analogue: beraprost.

D I Kim1, J Kambayashi, T Shibuya, M Sakon, T Kawasaki, T Mori.   

Abstract

The aim of this study was to evaluate the effect of a novel prostaglandin I2 analogue, beraprost (BPT), on the pseudointimal hyperplasia (PIH) of polytetrafluoroethylene (PTFE) prostheses. A total of 12 rabbits were equally divided into three groups. The control group was given a placebo daily, group 1 was given BPT orally 2 mg/kg per day, and group 2 was given BPT orally 4 mg/kg b.i.d. Exactly 1 cm of the inferior vena cava was resected and replaced by a 3-cm PTFE tube graft. All the grafts were patent when harvested 4 weeks after implantation, but the lumens were narrowed to various extents by PIH. PIH, determined by the dry weight of the intraluminal tissue deposit, was significantly (P < 0.01) suppressed in groups 1 and 2 compared with the control group. High-magnification light microscopy with various staining methods revealed the PIH to be composed mainly of smooth muscle cells (SMCs) and collagen fibrils in all three groups. Transmission electron microscopy revealed that the majority of SMCs in groups 1 and 2 were contractile in form, in contrast with the synthetic form seen in the control group. In conclusion, BPT attenuated the PIH of PTFE grafts by inhibiting the phenotype change in the SMCs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520167     DOI: 10.1007/BF00311489

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  33 in total

1.  Human vascular smooth muscle in culture. Growth and ultrastructure.

Authors:  M A Gimbrone; R S Cotran
Journal:  Lab Invest       Date:  1975-07       Impact factor: 5.662

2.  Myofibroblasts and myoepithelial cells in the chicken harderian gland.

Authors:  E del Cacho; M Gallego; C Felices; J A Bascuas
Journal:  Histol Histopathol       Date:  1991-07       Impact factor: 2.303

3.  Human vascular endothelial cells in culture. Lack of response to serum growth factors.

Authors:  C C Haudenschild; D Zahniser; J Folkman; M Klagsbrun
Journal:  Exp Cell Res       Date:  1976-03-01       Impact factor: 3.905

4.  Polytetrafluoroethylene grafts in the peripheral venous circulation of rabbits.

Authors:  E W Friedman; A J Hamilton
Journal:  Am J Surg       Date:  1983-09       Impact factor: 2.565

5.  Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo.

Authors:  H Sinzinger; T Zidek; P Fitscha; J O'Grady; O Wagner; J Kaliman
Journal:  Prostaglandins       Date:  1987-06

6.  Regulation of insulin-like growth factor I receptors on vascular smooth muscle cells by growth factors and phorbol esters.

Authors:  J J Ververis; L Ku; P Delafontaine
Journal:  Circ Res       Date:  1993-06       Impact factor: 17.367

7.  Prostacyclin synthesis by proliferative aortic smooth muscle cells. A kinetic in vivo and in vitro study.

Authors:  J Larrue; D Daret; J Demond-Henri; C Allières; H Bricaud
Journal:  Atherosclerosis       Date:  1984-01       Impact factor: 5.162

8.  Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates.

Authors:  P O Hagen; Z G Wang; E M Mikat; D B Hackel
Journal:  Ann Surg       Date:  1982-03       Impact factor: 12.969

9.  Differences in the stability of prostacyclin in human, rabbit and rat plasma.

Authors:  K E El Tahir; K I Williams; D J Betteridge
Journal:  Prostaglandins Leukot Med       Date:  1983-02

10.  Subcellular fractionation and morphology of calf aortic smooth muscle cells. Studies on whole aorta, aortic explants, and subcultures grown under different conditions.

Authors:  S Fowler; H Shio; H Wolinsky
Journal:  J Cell Biol       Date:  1977-10       Impact factor: 10.539

View more
  1 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.